The glucagon-like peptides: Pleiotropic regulators of nutrient homeostasis

Annals of the New York Academy of Sciences

Volumn 1070, Issue , 2006, Pages 10-26

  Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Absorption; Beta cell; Digestion; GLP 1; GLP 2; Glucagon; Growth; Insulin; Intestine; Motility; Nutrient; Satiety; Secretion

Indexed keywords

ATROPINE; DRUG ANALOG; EXENDIN 4; GLICENTIN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; OXYNTOMODULIN; PEPTIDE YY; SODIUM GLUCOSE COTRANSPORTER 1; TEDUGLUTIDE; UNCLASSIFIED DRUG;

CELLULAR DISTRIBUTION; CONFERENCE PAPER; DIABETES CONTROL; DIGESTION; ENERGY BALANCE; ENZYME ACTIVITY; FEEDBACK SYSTEM; FOOD INTAKE; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE TRANSPORT; HORMONE RELEASE; HUMAN; INTESTINE ABSORPTION; INTESTINE BLOOD FLOW; INTESTINE CRYPT; INTESTINE DISTENSION; INTESTINE FUNCTION DISORDER; INTESTINE MUCOSA; NAUSEA; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT MANAGEMENT; NUTRIENT UPTAKE; PANCREAS ISLET; PLEIOTROPY; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH EMPTYING; TASTE AVERSION; VAGUS NERVE; WEIGHT REDUCTION;

EID: 33746467477     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1317.006     Document Type: Conference Paper

References (116)

1. LEE, Y.C., P.L. BRUBAKER & D.J. DRUCKER. 1990. Developmental and tissue-specific regulation of proglucagon gene expression. Endocrinology 127: 2217-2222.
2. DHANVANTARI, S., N.G. SEIDAH & P.L. BRUBAKER. 1996. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol. Endocrinol. 10: 342-355.
3. ROUILLÉ, Y., G. WESTERMARK, S.K. MARTIN & D.F. STEINER. 1994. Proglucagon is processed to glucagon by prohormone convertase PC2 in αTC1-6 cells. Proc. Natl. Acad. Sci. USA 91: 3242-3246.
4. LEFÈBVRE, P.J. 1995. Glucagon and its family revisited. Diabetes Care 18: 715-730.
5. MOJSOV, S., G.C. WEIR & J.F. HABENER. 1987. Insulinotropin: glucagon-like peptide I(7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79: 616-619.
6. DRUCKER, D.J., P. EHRLICH, S.L. ASA & P.L. BRUBAKER. 1996. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 93: 7911-7916.
7. EISSELE, R., R. GÖKE, S. WILLEMER, et al. 1992. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22: 283-291.
8. D'ALESSIO, D., R. THIRLBY, L. LASCHANSKY, et al. 1993. Response of tGLP-1 to nutrients in humans. Digestion 54: 377-379.
9. XIAO, Q., R. BOUSHEY, D.J. DRUCKER & P.L. BRUBAKER. 1999. Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans. Gastroenterology 117: 99-105.
10. ROBERGE, J.N. & P.L. BRUBAKER. 1993. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133: 233-240.
11. ROBERGE, J.N., K.A. GRONAU & P.L. BRUBAKER. 1996. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137: 2383-2388.
12. ROCCA, A.S. & P.L. BRUBAKER. 1999. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 1687-1694.
13. PERSSON, K., R.L. GINGERICH, S. NAYAK, et al. 2000. Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am. J. Physiol Endocrinol. Metab. 279: E956-E962.
14. KNAPPER, J.M., A. HEATH, J.M. FLETCHER, et al. 1995. GIP and GLP-1(7-36)amide secretion in response to intraduodenal infusions of nutrients in pigs. Comp Biochem. Physiol C. Pharmacol. Toxicol. Endocrinol. 111: 445-450.
15. SCHIRRA, J., M. KATSCHINSKI, C. WEIDMANN, et al. 1996. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest 97: 92-103.
16. ANINI, Y., T. HANSOTIA & P.L. BRUBAKER. 2002. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143: 2420-2426.
17. ANINI, Y. & P.L. BRUBAKER. 2003. Muscaranic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144: 3244-3250.
18. BALKS, H.J., J.J. HOLST, A. VON ZUR MÜHLEN & G. BRABANT. 1997. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J. Clin. Endocrinol. Metab. 82: 786-790.
19. ABELLO, J., F. YE, A. BOSSHARD, et al. 1994. Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. Endocrinology 134: 2011-2017.
20. NAUCK, M.A., M.M. HEIMESAAT, C. ORSKOV, et al. 1993. Preserved incretin activity of glucagon-like peptide 1 [7- 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91: 301-307.
21. DUMOULIN, V., T. DAKKA, P. PLAISANCIE, et al. 1995. Regulation of glucagon-like peptide-1-(7-36)amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 136: 5182-5188.
22. PLAISANCIE, P., C. BERNARD, J.-A. CHAYVIALLE & J.-C. CUBER. 1994. Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology 135: 2398-2403.
23. ANINI, Y. & P.L. BRUBAKER. 2003. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52: 252-259.
24. LIM, G. & P.L. BRUBAKER. 2006. The effect of insulin resistance on glucagon-like peptide-1 (GLP-1) secretion in mouse enteroendocrine cells [abstract]. Diabetes 55: 364.
25. RANGANATH, L.R., J.M. BEETY, L.M. MORGAN, et al. 1996. Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 38: 916-919.
26. RASK, E., T. OLSSON, S. SODERBERG, et al. 2001. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diab. Care 24: 1640-1645.
27. VILSBOLL, T., T. KRARUP, C.F. DEACON, et al. 2001. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613.
28. VILSBOLL, T., H. AGERSO, T. KRARUP & J.J. HOLST. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab 88: 220-224.
29. DUMOULIN, V., F. MORO, A. BARCELO, et al. 1998. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139: 3780-3786.
30. REIMANN, F. & F.M. GRIBBLE. 2002. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51: 2757-2763.
31. GRIBBLE, F.M., L. WILLIAMS, A.K. SIMPSON & F. REIMANN. 2003. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52: 1147-1154.
32. FERRARIS, R.P., S. YASHARPOUR, K.C.K. LLOYD, et al. 1990. Luminal glucose concentrations in the gut under normal conditions. Am. J. Physiol. Gastrointest. Liver Physiol. 259: G822-G837.
33. REIMER, R.A., C. DARIMONT, S. GREMLICH, et al. 2001. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142: 4522-4528.
34. MODIGLIANI, R., J.C. RAMBAUD & J.J. BERNIER. 1973. The method of intraluminal perfusion of the human small intestine. II. Absorption studies in health. Digestion 9: 264-290.
35. LIN, H.C., X.T. ZHAO & L. WANG. 1996. Fat absorption is not complete by midgut but is dependent on load of fat. Am. J. Physiol 271: G62-G67.
36. HIRASAWA, A., K. TSUMAYA, T. AWAJI, et al. 2005. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11: 90-94.
37. ROCCA, A.S. & P.L. BRUBAKER. 1995. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 136: 5593-5599.
38. IAKOUBOV, R., C.I. WHITESIDE & P.L. BRUBAKER. 2004. Protein kinase C zeta activation and translocation are required for fatty acid-induced secretion of GLP-1 in intestinal endocrine L cells [abstract]. Eur. Assoc. Study Diab. 16A.
39. BRUBAKER, P.L., A. IZZO, M. HILL & D.J. DRUCKER. 1997. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. Endocrinol. Metab. 272: E1050-E1058.
40. BURRIN, D.G., B. STOLL, R. JIANG, et al. 2000. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G1249-G1256.
41. ORSKOV, C., B. HARTMANN, S.S. POULSEN, et al. 2005. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul. Pept. 124: 105-112.
42. GHATEI, M.A., R.A. GOODLAD, S. TAHERI, et al. 2001. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig. Dis. Sci. 46: 1255-1263.
43. BURRIN, D.G., B. STOLL, X. GUAN, et al. 2005. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 146: 22-32.
44. TSAI, C.H., M. HILL, S.L. ASA, et al. 1997. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. Endocrinol. Metab. 273: E77-E84.
45. SHIN, E.D., J.L. ESTALL, A. IZZO, et al. 2005. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128: 1340-1353.
46. BOUSHEY, R.P., B. YUSTA & D.J. DRUCKER. 1999. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. Endocrinol. Metab. 277: E937-E947.
47. BOUSHEY, R.P., B. YUSTA & D.J. DRUCKER. 2001. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 61: 687-693.
48. L'HEUREUX, M.-C. & P.L. BRUBAKER. 2003. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J. Pharm. Exp. Ther. 306: 347-354.
49. PRASAD, R., K. ALAVI & M.Z. SCHWARTZ. 2000. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J. Ped. Surg. 35: 357-359.
50. ALAVI, K., M.Z. SCHWARTZ, J.P. PALAZZO & R. PRASAD. 2000. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J. Pediatr. Surg. 35: 847-851.
51. BENJAMIN, M.A., D.M. MCKAY, P.C. YANG, et al. 2000. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47: 112-119.
52. SCOTT, R.B., D. KIRK, W.K. MACNAUGHTON & J.B. MEDDINGS. 1998. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 275: G911-G921.
53. WASHIZAWA, N., L.H. GU, L. GU, et al. 2004. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J. Parenter. Enteral Nutr. 28: 399-409.
54. MARTIN, G.R., L.E. WALLACE & D.L. SIGALET. 2004. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am. J. Physiol Gastrointest. Liver Physiol 286: G964-G972.
55. CHEESEMAN, C.I. 1997. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 273: R1965-R1971.
56. CHEESEMAN, C.I. & D. O'NEILL. 1998. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Exp. Physiol. 83: 605-616.
57. GUAN, X., B. STOLL, X. LU, et al. 2003. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125: 136-147.
58. KITCHEN, P.A., A.J. FITZGERALD, R.A. GOODLAD, et al. 2000. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G425-G428.
59. JEPPESEN, P.B., B. HARTMANN, J. THULESEN, et al. 2001. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806-815.
60. YUSTA, B., R. SOMWAR, F. WANG, et al. 1999. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J. Biol. Chem. 274: 30459-30467.
61. YUSTA, B., J. ESTALL & D.J. DRUCKER. 2002. Glucagon-like peptide-2 receptor activation engages bad and glucagon synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidyl-inositol 3-kinase. J. Biol. Chem. 277: 24896-24906.
62. JASLEEN, J., N. SHIMODA, E.R. SHEN, et al. 2000. Signaling mechanisms of glucagon-like peptide 2-induced intestinal epithelial cell proliferation. J. Surg. Res. 90: 13-18.
63. YUSTA, B., L. HUANG, D. MUNROE, et al. 2000. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744-755.
64. BJERKNES, M. & H. CHENG. 2001. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc. Natl. Acad. Sci. USA 98: 12497-12502.
65. DUBE, P.E., C.L. FORSE, J. BAHRAMI, et al. In Press. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology.
66. DUBE, P.E. & P.L. BRUBAKER. 2005. Glucagon-like peptide-2 acutely activates PKB/Akt and decreases apoptotic signaling in the mouse small intestine [abstract]. Gastroenterology 128: 1295A.
67. KREYMANN, B., M.A. GHATEI, G. WILLIAMS & S.R. BLOOM. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304.
68. NAUCK, M.A., A. SAUERWALD, R. RITZEL, et al. 1998. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21: 1925-1931.
69. TOFT-NIELSEN, M.B., S. MADSBAD & J.J. HOLST. 1999. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143.
70. GUTNIAK, M.K., B. LINDE, J.J. HOLST & S. EFENDIC. 1994. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17: 1039-1044.
71. CREUTZFELDT, W. 2005. The [pre-] history of the incretin concept. Regul. Pept. 128: 87-91.
72. SCROCCHI, L.A., B.A. MARSHALL, S.M. COOK, et al. 1998. Identification of glucagon-like peptide 1 (GEP-1) actions essential for glucose homeostasis in mice with disruption of GLP- 1 receptor signaling. Diabetes 47: 632-639.
73. 2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48: 1979-1986.
74. HANSOTIA, T., L.L. BAGGIO, D. DELMEIRE, et al. 2004. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53: 1326-1335.
75. DRUCKER, D.J., J. PHILIPPE, S. MOJSOV, et al. 1987. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 84: 3434-3438.
76. HELLER, R.S., T.J. KIEFFER & J.F. HABENER. 1997. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 46: 785-791.
77. THORENS, B. 1992. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 89: 8641-8645.
78. GROMADA, J., K. BOKVIST, W.G. DING, et al. 1998. Glucagon-like peptide 1(7-36) amide stimulates exocytosis in human pancreatic β-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47: 57-65.
79. MONTROSE-RAFIZADEH, C., P. AVDONIN, M.J. GARANT, et al. 1999. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140: 1132-1140.
80. XU, G., D.A. STOFFERS, J.F. HABENER & S. BONNER-WEIR. 1999. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
81. WANG, Q. & P.L. BRUBAKER. 2002. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273.
82. LI, Y., T. HANSOTIA, B. YUSTA, et al. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278: 471-478.
83. POSPISILIK, J.A., J. MARTIN, T. DOTY, et al. 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750.
84. WANG, Q., L. LI, E. XU, et al. 2004. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of PKB in pancreatic (INS-1) beta-cells. Diabetologia 47: 478-487.
85. BUTEAU, J., S. FOISY, C.J. RHODES, et al. 2001. Protein kinase Czeta activation mediates glucagon-like peptide-1- induced pancreatic beta-cell proliferation. Diabetes 50: 2237-2243.
86. DE LEON D.D., S. DENG, R. MADANI, et al. 2003. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52: 365-371.
87. FARILLA, L., H. HUI, C. BERTOLOTTO, et al. 2002. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408.
88. TOURREL, C., D. BAILBE, M.J. MEILE & B. PORTHA. 2001. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562-1570.
89. ALCÁNTARA, A.I., M. MORALES, E. DELGADO, et al. 1997. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch. Biochem. Biophys. 341: 1-7.
90. MÁRQUEZ, L., M.A. TRAPOTE, M.A. LUQUE, et al. 1998. Inositolphosphoglycans possibly mediate the effects of glucagon- like peptide-1(7-36)amide on rat liver and adipose tissue. Cell Biochem. Funct. 16: 51-56.
91. IONUT, V., K. HUCKING, I.F. LIBERTY & R.N. BERGMAN. 2005. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48: 967-975.
92. DARDEVET, D., M.C. MOORE, C.A. DICOSTANZO, et al. 2005. Insulin secretion-independent effects of glucagon-like peptide 1 (GLP-1) on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am. J. Physiol Gastrointest. Liver Physiol. 289: G 806-814.
93. NAKAGAWA, A., H. SATAKE, H. NAKABAYASHI, et al. 2004. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 110: 36-43.
94. AHREN, B. 2004. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am. J. Physiol Regul. Integr. Comp Physiol 286: R269-R272.
95. SZAYNA, M., M.E. DOYLE, J.A. BETKEY, et al. 2000. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141: 1936-1941.
96. EGAN, J.M., G.S. MENEILLY & D. ELAHI. 2003. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am. J. Physiol Endocrinol. Metab 284: E1072-E1079.
97. HARDER, H., L. NIELSEN, D.T. TU & A. ASTRUP. 2004. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27: 1915-1921.
98. ZANDER, M., S. MADSBAD, J.L. MADSEN & J.J. HOLST. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
99. AHREN, B., G. PACINI, J.E. FOLEY & A. SCHWEIZER. 2005. Improved meal-related {beta}-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28: 1936-1940.
100. KENDALL, D.M., M.C. RIDDLE, J. ROSENSTOCK, et al. 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091.
101. 2005. Exenatide (Byetta) for type 2 diabetes. Med. Lett. Drugs Ther. 47: 45-46.
102. NASLUND, E., B. BARKELING, N. KING, et al. 1999. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GEP-1) in obese men. Int. J. Obes. Relat Metab Disord. 23: 304-311.
103. RODRIQUEZ, D.F., M. NAVARRO, E. ALVAREZ, et al. 2000. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49: 709-717.
104. TALSANIA, T., Y. ANINI, S. SIU, et al. 2005. Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756.
105. BAGGIO, L.L., Q. HUANG, T.J. BROWN & D.J. DRUCKER. 2004. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GEP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492-2500.
106. KASTIN, A.J., V. AKERSTROM & W. PAN. 2002. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18: 7-14.
107. DAKIN, C.L., C.J. SMALL, R.L. BATTERHAM, et al. 2004. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687-2695.
108. NASLUND, E., N. KING, S. MANSTEN, et al. 2004. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 91: 439-446.
109. BOZKURT, A., E. NASLÜND, J.J. HOLST & P.M. HELLSTRÖM. 2002. GEP-1 and GEP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Reg. Pep. 107: 129-135.
110. NAGELL, C.F., A. WETTERGREN, J.F. PEDERSEN, et al. 2004. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand. J. Gastroenterol. 39: 353-358.
111. KIRKEGAARD, P., A.J. MOODY, J.J. HOLST, et al. 1982. Glicentin inhibits gastric acid secretion in the rat. Nature 297: 156-157.
112. JARROUSSE, C., C. CARLES-BONNET, H. NIEL & D. BATAILLE. 1993. Inhibition of gastric acid secretion by oxyntomodulin and its (19-37) fragment in the conscious? rat. Am. J. Physiol. Gastrointest. Liver Physiol. 264: G816-G823.
113. PELLISSIER, S., K. SASAKI, D. LE NGUYEN, et al. 2004. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol. Motil. 16: 455-463.
114. WILLMS, B., J. WERNER, J.J. HOLST, et al. 1996. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon- like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin- dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81: 327-332.
115. PEDERSON, R.A., H.A. WHITE, D. SCHLENZIG, et al. 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253-1258.
116. TAVARES, W., D.J. DRUCKER & P.L. BRUBAKER. 2000. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am. J. Physiol. Endocrinol. Metab. 278: E134-E139.